Literature DB >> 29629524

Glucose Hypometabolism in Hippocampal Subdivisions in Alzheimer's Disease: A Pilot Study Using High-Resolution ¹⁸F-FDG PET and 7.0-T MRI.

Eun Jung Choi1, Young Don Son1,2, Young Noh3, Hyon Lee3, Young Bo Kim4, Kee Hyung Park5.   

Abstract

BACKGROUND AND
PURPOSE: Atrophy of the hippocampus is an important clinical diagnostic marker of Alzheimer's disease (AD), and so assessments of hippocampal activity and its subdivisions might provide invaluable information. This study compared the glucose metabolism of hippocampal subdivisions in mild-AD patients and healthy controls.
METHODS: High-resolution T2*-weighted gradient-echo magnetic resonance imaging (MRI) images and ¹⁸F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) images were acquired using 7.0-T MRI and high-resolution research tomograph FDG-PET, respectively, in 9 early-stage AD patients and 10 healthy subjects. The hippocampal body was divided into three equal parts (anterior, middle, and posterior), and in each part a region of interest (ROI) was drawn over the cornus ammonis (CA)1, CA2/3, CA4/dentate gyrus (DG), and subiculum. The standardized uptake values of the hippocampal subdivisions were calculated for each ROI as ratios relative to the pons standardized uptake value. Statistical analysis was conducted using the Mann-Whitney U test.
RESULTS: Patients with early-stage AD patients showed significantly less metabolic activity than healthy controls focally in the middle (p=0.050) and posterior (p=0.034) CA2/3 regions of the right hippocampus, and significantly less activity throughout the left hippocampal body in the anterior CA2/3 (p=0.027) and CA4/DG (p=0.027) regions, the middle CA1 region (p=0.011), and the posterior CA1 (p=0.034), CA2/3 (p=0.007), and CA4/DG (p=0.014) regions.
CONCLUSIONS: It was possible to use high-resolution PET-MRI fusion images to identify hippocampus subdivisions and assess glucose metabolism in the subfields. Reductions in metabolic activity were found to vary along the hippocampal axis in early-stage AD patients.
Copyright © 2018 Korean Neurological Association.

Entities:  

Keywords:  Alzheimer's disease; fluorodeoxyglucose; hippocampus; hypometabolism

Year:  2018        PMID: 29629524      PMCID: PMC5897197          DOI: 10.3988/jcn.2018.14.2.158

Source DB:  PubMed          Journal:  J Clin Neurol        ISSN: 1738-6586            Impact factor:   3.077


INTRODUCTION

Memory impairment is the most common and earliest symptoms of Alzheimer's disease (AD). Atrophy of the mesial temporal lobe–and especially of the hippocampus–as detected in neuroimaging is known to be related to episodic memory impairment, and thus is used as an important marker for the clinical diagnosis of AD. The hippocampus1 is structurally complex and composed of the four parts of the cornus ammonis (CA1–4), the dentate gyrus (DG), and the subiculum. These regions have different structures234 as determined by in-vitro and ex-vivo histological methods.1 The small size of the hippocampus makes it difficult to identify and segment the hippocampal subdivisions in magnetic resonance imaging (MRI). MRI at 3 tesla (T) provides performance that is sufficient for general cases but not for delineating the hippocampal subdivisions, and so studies employing 3-T MRI have focused on structural and functional changes in the entire hippocampi and other brain regions.5 However, 7-T MRI provides a higher signal-to-noise ratio and thus a high spatial resolution, which allows better segmentation of the subdivisions of the human hippocampus.67 For example, volumetric analyses of hippocampal subdivisions in AD patients have revealed significant volume losses in CA1 and the entorhinal cortex,8 with these losses being correlated with memory performance.9 Positron-emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is commonly used for clinical imaging in AD and is an important indicator of neuronal injury,1011 but its usefulness is restricted by its relatively low spatial resolution. Recently introduced brain-dedicated, high-resolution research tomograph (HRRT) PET scanners12 have a spatial resolution of up to 2.5 mm full width at half maximum, but even this is inadequate for identifying important small brain subdivisions. However, Cho et al.13 combined anatomical information obtained by high-resolution MRI with HRRT-PET images to successfully assess glucose metabolism in the hippocampal subdivisions of healthy subjects. The present study applied the same combination of high-resolution two-dimensional T2*-weighted gradient-echo MRI and FDG-PET imaging protocols to mild-AD patients and cognitively healthy subjects in order to determine whether these technologies in combination could identify changes in glucose metabolism within the hippocampal subdivisions in AD patients.

METHODS

Participants

This study included 19 participants, comprising 9 early-stage AD patients and 10 healthy control subjects. The AD patients met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD.14 The cognitive statuses in both groups were assessed using the Seoul Neuropsychological Screening Battery,15 which is used as a standardized neuropsychological battery in Korea that includes the Korean version of the Mini Mental State Examination and the digit span test, the Rey Complex Figure Test and Recognition Trial, the Seoul Verbal Learning Test, and the Controlled Oral Word Association Test. Age-matched healthy controls that met the following conditions were included: 1) no history of a neurological or psychiatric disorder, 2) normal cognitive function as determined by neuropsychological tests, and 3) able to perform the normal activities of daily living. The study was approved by the Institutional Review Board of Gil Medical Center, and all participants signed an informed-consent form (IRB No. H-0907-014-038).

Neuroimaging data acquisition

Data were acquired using systematically calibrated HRRT-PET (Siemens, Knoxville, TN, USA) and 7.0-T MRI (Siemens, Erlangen, Germany) scanners as described previously.13 Forty minutes after the intravenous injection of 185 MBq of FDG, participants underwent a 30-minute HRRT-PET scan and a 6-minute transmission scan for attenuation correction. HRRT-PET images were reconstructed using the three-dimensional ordinary Poisson ordered-subsets expectation-maximization algorithm. The imaging resolution was 1.22×1.22×1.22 mm3. MRI scans were then conducted at 7.0 T16 using an in-house-manufactured eight-channel radiofrequency transmitter and receiver coil. Two-dimensional T2*-weighted gradient-echo images were obtained using the following parameters: repetition time, 750 ms; echo time, 21 ms; flip angle, 30°; resolution, 0.2×0.2×2.0 mm3; imaging orientation, coronal; and 17 slices. The imaging orientation in the coronal plane was perpendicular to the longitudinal axis of the hippocampal body. Imaging planes were set on the hippocampal body at a uniform distance of 4 mm, which included a 2-mm interplane gap.

Data analysis

This study analyzed only the hippocampal body (i.e., not the head or tail) due to the limitation of the number of slices at the high resolution used. The middle slice of the 17 slices was placed at the middle of the longitudinal axis of the hippocampus. The hippocampal body was divided equally along the longitudinal axis into three divisions: anterior, middle, and posterior (Fig. 1A). The first five slices toward the hippocampal head covered the anterior part, the last five slices toward the hippocampal tail covered the posterior part, and the middle five slices excluding both ends covered the middle part. Regions of interest (ROIs) were drawn in the following hippocampal subfields: CA1, CA2/3, CA4/DG, and subiculum (Fig. 1B). The hippocampal subfields were segmented based on previously described criteria.17 CA4/DG were drawn as an almost elliptical shape in the middle of the hippocampus. A line crossing CA4/DG from the hippocampal sulcus to the outer edge of the temporal horn was drawn as the reference line. An upward perpendicular line dividing the reference line in half indicated the boundary between CA2/3 and CA1. CA1 extended until meeting the hippocampal sulcus at the edge of CA4/DG. The end of the subiculum was positioned at the most-medial point of the temporal cortex.
Fig. 1

ROIs in the hippocampal subfields and three divisions of the hippocampal body along the hippocampus. (A) Slice positions in the sagittal reference images. Each of the five slices from the hippocampal head to tail were divided into the anterior (Ant, yellow), middle (Mid, red), and posterior (Post, blue) parts. The separating slices (white dotted lines) were not included in the data analysis. (B) Hippocampal ROIs drawn in the coronal planes. A line crossing the CA4/DG region from the hippocampal sulcus to the outer edge of the temporal horn was drawn as the reference line. A perpendicular line dividing the reference line in half defined the boundary between CA2/3 and CA1. The boundary between CA1 and the subiculum (Sub) was placed at the hippocampal sulcus. CA: cornus ammonis, DG: dentate gyrus, ROI: region of interest.

To allow comparisons with conventional analyses, ROIs of the entire hippocampal body in each subfield were synthesized from longitudinally segmented ROIs. The FDG uptake values in the hippocampal subdivisions were measured using the corresponding ROIs. Standardized uptake values were calculated as ratios relative to the standardized uptake value for the pons, and were obtained by manually drawing ROIs in the five sagittal planes. Hippocampus and pons ROIs were drawn manually on 7.0-T MRI images using Vinci software (version 2.54, Max Planck Institute for Neurological Research, Cologne, Germany) by two trained specialists. The intrarater reliability was considered satisfactory when the intraclass correlation coefficient was >0.85, as calculated using SPSS Statistics software (version 21, IBM Corp., Armonk, NY, USA). Group comparisons were performed using the Mann-Whitney U test implemented in SPSS software. An asymptotic two-tailed significance probability of <0.05 was considered statistically significant.

RESULTS

As indicated in Table 1, cognitive functioning was significantly worse in AD patients than in controls. The standardized uptake ratios of the entire hippocampal body revealed that glucose metabolism was significantly lower in the AD group than in the control group in the left CA2/3 (p=0.027) and CA4/DG (p=0.018) (Fig. 2).
Table 1

Brief demographics of the participants

Control (n=10)AD (n=9)p
Age, years57 (53.8–65.0)63 (52–67)0.909
Sex, M/F1/93/60.213
Education, years12 (10.5–13.0)9 (5–12)0.006*
K-MMSE28 (26.0–29.3)21 (18–25)0.001*
CDR0 (0–0)0.5 (0.5–0.5)<0.001*
CDR-SOB0 (0–0)3 (2.0–3.5)<0.001*

Data are median (interquartile range) values for nonnormally distributed variables.

*Statistically significant at p<0.01, †Mann-Whitney U test, ‡Fisher's exact test.

AD: Alzheimer's disease, CDR: Clinical Dementia Rating, F: female, K-MMSE: Korean version of the Mini-Mental State Examination, M: male, SOB: Sum of Boxes.

Fig. 2

Superimposed 7.0-T MRI images and HRRT-PET images of bilateral hippocampi in a healthy subject (A) and an early-stage AD patient (B). HRRT-PET images were produced using the same thresholds in healthy controls and AD patients. The white and black arrows indicate the location of the hippocampus. (C) Glucose metabolism quantified in the entire hippocampi. The asterisks indicate significant differences at p<0.05. Data are mean and SD values. AD: Alzheimer's disease, CA: cornus ammonis, DG: dentate gyrus, HRRT: high-resolution research tomograph, MRI: magnetic resonance imaging, PET: positron-emission tomography.

The AD group showed significantly lower glucose metabolism in CA2/3 of the middle (p=0.050) and posterior (p=0.034) regions of the right hippocampal body compared to controls. In the left hippocampal body, glucose metabolism was significantly lower in the anterior (p=0.027) and posterior (p=0.007) regions of CA2/3, the anterior (p=0.027) and posterior (p=0.014) regions of CA4/DG, and the middle (p=0.011) and posterior (p=0.034) regions of CA1 in AD patients (Fig. 3).
Fig. 3

Distribution of glucose metabolism within subfields along longitudinal axis of hippocampus. (A) Representative manually drawn ROIs on 7.0-T MRI images. ROIs were drawn on each slice along the longitudinal axis of the hippocampus bilaterally, and the hippocampus was divided into anterior, middle, and posterior parts. (B) Glucose metabolism in the right hippocampus. (C) Glucose metabolism in the left hippocampus. The asterisks indicate significant differences at p<0.05. Data are mean and SD values. AD: Alzheimer's disease, CA: cornus ammonis, DG: dentate gyrus, MRI: magnetic resonance imaging, ROI: region of interest.

DISCUSSION

This study measured glucose metabolism in hippocampal subdivisions along the longitudinal axis of the hippocampus using high-resolution FDG-PET and 7.0-T MRI in early-stage AD patients and healthy controls. Until recently, the resolving power of FDG-PET was inadequate for studying changes in the metabolism of glucose in the hippocampal subdivisions of AD patients. However, the high spatial resolution of HRRT-PET and 7.0-T MRI systems has made it possible to segment and assess glucose metabolism in the hippocampal subfields. T2*-weighted MRI at 7.0 T makes it possible to delineate hippocampal substructures with higher definition, making hippocampal segmentation possible.17 In a previous study, we were able to assess glucose metabolism in the hippocampus subdivisions in healthy control subjects using these high-spatial-resolution imaging systems.13 The present study identified differences in glucose metabolism between cognitively normal subjects and AD patients along the longitudinal axis of the hippocampus body in specific hippocampal subfields. Overall, glucose hypometabolism in the AD group was more dominant in the left than the right hippocampus and more pronounced in the CA2/3 region than in the other hippocampal subdivisions. In the CA1 region, which is known to be affected during early-stage AD,81819 the glucose metabolism was significantly lower in the middle and posterior body of the left hippocampus in the AD group. The glucose metabolism in the CA2/3 region was significantly lower in the middle and posterior body of the right hippocampus and in the anterior and posterior body of the left hippocampus. In the CA4/DG region, the glucose metabolism in the AD group was significantly lower in the anterior and posterior body of the left hippocampus. It is well established that volume loss of the hippocampus is most frequently observed in the CA1 region in AD patients,20 although CA2/3, CA4/DG, and the subiculum have been shown to be dominantly affected in several studies of mild cognitive impairment (MCI) and AD.21222324 In addition, the higher degree of glucose hypometabolism in the left hippocampus is consistent with the loss of gray matter in the left hemisphere was associated with impaired language function in MCI and AD patients.25 A notable feature of our results is that they differ from those of previous studies because our data directly reflect functional changes (i.e., differences in glucose metabolism) rather than structural changes in the hippocampus. There is evidence from several studies that the relation between functional and structural changes is dependent on the level of progression in many diseases, including AD. The present study minimized the effects of hippocampal atrophy and the partial volume effect by using manual segmentation and a point-spread-function deconvolution algorithm, respectively. Nonetheless, the CA2/3 region could still have been affected by such confounders due to its diminutive size. Furthermore, our analysis was applied to subdivisions of the hippocampal body rather than the entire hippocampi, and the hippocampal head constitutes a major part of CA1; this means that a sizeable part of CA1 was not included in our analysis. This study was subject to several limitations. First, due to its preliminary nature, the number of subjects was too small to allow clinical conclusions to be drawn. Studies involving larger numbers of subjects are therefore required to confirm our findings. Second, our evaluation was limited by excluding the hippocampal head and tail, which was due to the limitation of the number of slices at the resolution used. Third, the AD patients enrolled were relatively young (mostly younger than 65 years), and hippocampal sparing is common in early-onset AD.26 The intergroup differences in glucose metabolism were therefore probably smaller than might have been expected. Nonetheless, despite these limitations, this study has demonstrated that it is possible to observe structural and metabolic changes in the hippocampal subdivisions of AD patients. In conclusion, high-resolution PET-MRI fusion images enabled the identification of hippocampal subdivisions and assessments of glucose metabolism in the CA1, CA2/3, CA4/DG, and subiculum subfields in healthy control subjects and early-stage AD patients. Our findings suggest that the combination of high-resolution PET and MRI may be a useful tool for early AD detection.
  22 in total

1.  Substructural hippocampal glucose metabolism observed on PET/MRI.

Authors:  Zang-Hee Cho; Young-Don Son; Hang-Keun Kim; Sung-Tae Kim; Sang-Yoon Lee; Je-Geun Chi; Chan-Woong Park; Young-Bo Kim
Journal:  J Nucl Med       Date:  2010-09-16       Impact factor: 10.057

2.  Mild cognitive impairment: differential atrophy in the hippocampal subfields.

Authors:  B J Hanseeuw; K Van Leemput; M Kavec; C Grandin; X Seron; A Ivanoiu
Journal:  AJNR Am J Neuroradiol       Date:  2011-08-11       Impact factor: 3.825

3.  Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI.

Authors:  G A Kerchner; C P Hess; K E Hammond-Rosenbluth; D Xu; G D Rabinovici; D A C Kelley; D B Vigneron; S J Nelson; B L Miller
Journal:  Neurology       Date:  2010-10-12       Impact factor: 9.910

4.  Hippocampal CA1 apical neuropil atrophy and memory performance in Alzheimer's disease.

Authors:  Geoffrey A Kerchner; Gayle K Deutsch; Michael Zeineh; Robert F Dougherty; Manojkumar Saranathan; Brian K Rutt
Journal:  Neuroimage       Date:  2012-07-03       Impact factor: 6.556

5.  Measurement of hippocampal subfields and age-related changes with high resolution MRI at 4T.

Authors:  S G Mueller; L Stables; A T Du; N Schuff; D Truran; N Cashdollar; M W Weiner
Journal:  Neurobiol Aging       Date:  2006-05-19       Impact factor: 4.673

Review 6.  Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective.

Authors:  Piotr Lewczuk; Barbara Mroczko; Anne Fagan; Johannes Kornhuber
Journal:  Adv Med Sci       Date:  2014-12-09       Impact factor: 3.287

7.  Automated hippocampal subfield segmentation in amnestic mild cognitive impairments.

Authors:  Hyun Kook Lim; Seung Chul Hong; Won Sang Jung; Kook Jin Ahn; Wang Youn Won; Changtae Hahn; In Seong Kim; Chang Uk Lee
Journal:  Dement Geriatr Cogn Disord       Date:  2012-07-02       Impact factor: 2.959

8.  Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients.

Authors:  Hyun-Jung Ahn; Juhee Chin; Aram Park; Byung Hwa Lee; Mee Kyung Suh; Sang Won Seo; Duk L Na
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

9.  Automated segmentation of hippocampal subfields in drug-naïve patients with Alzheimer disease.

Authors:  H K Lim; S C Hong; W S Jung; K J Ahn; W Y Won; C Hahn; I S Kim; C U Lee
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

10.  Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology.

Authors:  Bärbel Schönheit; Rosemarie Zarski; Thomas G Ohm
Journal:  Neurobiol Aging       Date:  2004-07       Impact factor: 4.673

View more
  9 in total

1.  Diffusion MRI-guided theta burst stimulation enhances memory and functional connectivity along the inferior longitudinal fasciculus in mild cognitive impairment.

Authors:  Yu-Chin Chen; Viet Ton That; Chidi Ugonna; Yilin Liu; Lynn Nadel; Ying-Hui Chou
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-20       Impact factor: 12.779

Review 2.  Future Prospects of Positron Emission Tomography-Magnetic Resonance Imaging Hybrid Systems and Applications in Psychiatric Disorders.

Authors:  Young-Don Son; Young-Bo Kim; Jong-Hoon Kim; Jeong-Hee Kim; Dae-Hyuk Kwon; Haigun Lee; Zang-Hee Cho
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-08

3.  The effect of chronic cerebral hypoperfusion on the pathology of Alzheimer's disease: A positron emission tomography study in rats.

Authors:  Jae-Hyung Park; Jeong-Ho Hong; Sang-Woo Lee; Hyun Dong Ji; Jung-Ah Jung; Kyung-Wha Yoon; Jung-In Lee; Kyoung Sook Won; Bong-Il Song; Hae Won Kim
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

4.  Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer's disease: a PET/MRI study.

Authors:  Yifan Chen; Junkai Wang; Chunlei Cui; Yusheng Su; Donglai Jing; LiYong Wu; Peipeng Liang; Zhigang Liang
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

5.  Selective neurodegeneration of the hippocampus caused by chronic cerebral hypoperfusion: F-18 FDG PET study in rats.

Authors:  Jung-In Lee; Ji Sun Lim; Jeong-Ho Hong; Shin Kim; Sang-Woo Lee; Hyun Dong Ji; Kyoung Sook Won; Bong-Il Song; Hae Won Kim
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

6.  Vascular mapping of the human hippocampus using Ferumoxytol-enhanced MRI.

Authors:  Sagar Buch; Yongsheng Chen; Pavan Jella; Yulin Ge; E Mark Haacke
Journal:  Neuroimage       Date:  2022-02-02       Impact factor: 7.400

7.  Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer's disease.

Authors:  Shaozhen Yan; Chaojie Zheng; Bixiao Cui; Zhigang Qi; Zhilian Zhao; Yanhong An; Liyan Qiao; Ying Han; Yun Zhou; Jie Lu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-10       Impact factor: 9.236

8.  Simultaneous FDG-PET/MRI detects hippocampal subfield metabolic differences in AD/MCI.

Authors:  Mackenzie L Carlson; Phillip S DiGiacomo; Audrey P Fan; Maged Goubran; Mohammad Mehdi Khalighi; Steven Z Chao; Minal Vasanawala; Max Wintermark; Elizabeth Mormino; Greg Zaharchuk; Michelle L James; Michael M Zeineh
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

9.  Treatment with Growth Hormone (GH) Increased the Metabolic Activity of the Brain in an Elder Patient, Not GH-Deficient, Who Suffered Mild Cognitive Alterations and Had an ApoE 4/3 Genotype.

Authors:  Jesús Devesa; Iria Núñez; Carlos Agra; Alejandro Bejarano; Pablo Devesa
Journal:  Int J Mol Sci       Date:  2018-08-05       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.